AR044599A1 - METHOD FOR REDUCING THE HARMFUL EFFECTS OF NICOTINE ADMINISTERED BY ORAL OR TRANSDERMAL - Google Patents
METHOD FOR REDUCING THE HARMFUL EFFECTS OF NICOTINE ADMINISTERED BY ORAL OR TRANSDERMALInfo
- Publication number
- AR044599A1 AR044599A1 ARP040101917A ARP040101917A AR044599A1 AR 044599 A1 AR044599 A1 AR 044599A1 AR P040101917 A ARP040101917 A AR P040101917A AR P040101917 A ARP040101917 A AR P040101917A AR 044599 A1 AR044599 A1 AR 044599A1
- Authority
- AR
- Argentina
- Prior art keywords
- tobacco
- nicotine
- reducing
- transdermal
- oral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/20—Biochemical treatment
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/24—Treatment of tobacco products or tobacco substitutes by extraction; Tobacco extracts
- A24B15/241—Extraction of specific substances
- A24B15/243—Nicotine
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/24—Treatment of tobacco products or tobacco substitutes by extraction; Tobacco extracts
- A24B15/241—Extraction of specific substances
- A24B15/245—Nitrosamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1077—Pentosyltransferases (2.4.2)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Manufacture Of Tobacco Products (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Abstract
Reducción de los efectos perniciosos de la nicotina administrada por vía oral o transdérmica en programas convencionales para abandonar el uso del tabaco. Más específicamente, las realizaciones se relacionan con métodos para reducir los efectos perniciosos de la ingesta de nicotina asociada con los programas convencionales para abandonar el uso del tabaco, donde se administran productos basados en tabaco que contienen una cantidad reducida de nicotina y nitrosaminas específicas de tabaco (TSNA). Reivindicación 1: Un método para preparar un tabaco mixto con un bajo contenido de nicotina caracterizado porque comprende: proporcionar un primer tabaco, proporcionar un segundo tabaco producido a partir de una planta de tabaco modificada genéticamente que presenta un nivel reducido de QPTasa, en comparación con una planta de tabaco no modificada de la misma variedad, y combinar el primer y el segundo tabaco para obtener dicho tabaco con un contenido de nicotina reducido.Reduction of the pernicious effects of nicotine administered orally or transdermally in conventional programs to quit tobacco use. More specifically, the embodiments relate to methods for reducing the pernicious effects of nicotine intake associated with conventional tobacco cessation programs, where tobacco-based products containing a reduced amount of nicotine and tobacco-specific nitrosamines are administered. (TSNA). Claim 1: A method for preparing a mixed tobacco with a low nicotine content characterized in that it comprises: providing a first tobacco, providing a second tobacco produced from a genetically modified tobacco plant having a reduced level of QPTase, as compared to an unmodified tobacco plant of the same variety, and combining the first and second tobacco to obtain said tobacco with a reduced nicotine content.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47594503P | 2003-06-04 | 2003-06-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR044599A1 true AR044599A1 (en) | 2005-09-21 |
Family
ID=33551567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040101917A AR044599A1 (en) | 2003-06-04 | 2004-06-03 | METHOD FOR REDUCING THE HARMFUL EFFECTS OF NICOTINE ADMINISTERED BY ORAL OR TRANSDERMAL |
Country Status (10)
Country | Link |
---|---|
US (1) | US20060237025A1 (en) |
EP (1) | EP1628681A4 (en) |
JP (1) | JP2007528204A (en) |
KR (1) | KR20060032141A (en) |
CN (1) | CN1812811A (en) |
AR (1) | AR044599A1 (en) |
AU (1) | AU2004251635A1 (en) |
CA (1) | CA2527648A1 (en) |
WO (1) | WO2005000352A1 (en) |
ZA (1) | ZA200510170B (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006124448A2 (en) | 2005-05-11 | 2006-11-23 | Vector Tobacco Inc. | Reduced risk tobacco products and methods of making same |
CN101742901A (en) * | 2007-06-01 | 2010-06-16 | 先正达参股股份有限公司 | Methods for the commercial production of transgenic plants |
US7667106B2 (en) * | 2007-11-06 | 2010-02-23 | Alliance One International, Inc. | Tobacco cultivar ‘AOB 175’ |
US7665472B2 (en) * | 2007-11-06 | 2010-02-23 | Alliance One International, Inc. | Tobacco cultivar AOB 175 and products therefrom |
AR075466A1 (en) | 2008-10-22 | 2011-04-06 | Basf Se | USE OF AUXINE TYPE HERBICIDES IN CULTIVATED PLANTS |
AR075465A1 (en) | 2008-10-22 | 2011-04-06 | Basf Se | USE OF SULFONILUREA HERBICIDES IN CULTIVATED PLANTS |
JP2015532274A (en) | 2012-10-01 | 2015-11-09 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | Use of N-thio-anthranilamide compounds in cultivated plants |
WO2014079820A1 (en) | 2012-11-22 | 2014-05-30 | Basf Se | Use of anthranilamide compounds for reducing insect-vectored viral infections |
CN102940310B (en) * | 2012-12-12 | 2015-08-05 | 广东中烟工业有限责任公司 | A kind of method of adjustment based on each component in the Cigarette design of N-nitrosamine burst size |
CN103005702B (en) * | 2012-12-12 | 2015-03-18 | 广东中烟工业有限责任公司 | Design method of less harmful cigarette based on harm index under deep smoking |
CN103005703B (en) * | 2012-12-12 | 2015-04-15 | 广东中烟工业有限责任公司 | Cigarette designing method based on smoke perniciousness index |
EP3028573A1 (en) | 2014-12-05 | 2016-06-08 | Basf Se | Use of a triazole fungicide on transgenic plants |
WO2016091674A1 (en) | 2014-12-12 | 2016-06-16 | Basf Se | Use of cyclaniliprole on cultivated plants |
BR112017021450B1 (en) | 2015-04-07 | 2021-12-28 | Basf Agrochemical Products B.V. | PEST CONTROL METHODS, PLANT HEALTH IMPROVEMENT METHOD AND COATED SEED |
EP3338552A1 (en) | 2016-12-21 | 2018-06-27 | Basf Se | Use of a tetrazolinone fungicide on transgenic plants |
JP7244024B2 (en) * | 2018-06-25 | 2023-03-22 | 学校法人近畿大学 | Collagen degradation inhibitor for blood vessel walls affected by nicotine intake |
CN114929880A (en) * | 2019-10-10 | 2022-08-19 | 奥驰亚客户服务有限公司 | QPT engineering based compositions and methods for producing tobacco plants and products with altered alkaloid levels |
CN113528537A (en) * | 2021-08-11 | 2021-10-22 | 云南省烟草农业科学研究院 | NtQPT2 gene mutant for reducing nicotine content in tobacco leaves and application thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993005646A1 (en) * | 1991-09-13 | 1993-04-01 | Technology Management Services, S.A. | Reduction of nicotine levels in tobacco |
AU4991500A (en) * | 1999-05-06 | 2000-11-21 | Michael Timko | Regulation of gene expression in tobacco for manipulation of plant growth and secondary metabolism |
ATE360707T1 (en) * | 2000-02-07 | 2007-05-15 | Remedios Cristobal Guiller Dos | BIOMOLECULAR TOXICITY TEST |
EP1313868B1 (en) * | 2000-08-30 | 2006-07-19 | North Carolina State University | Transgenic plants containing molecular decoys that alter protein content therein |
WO2002037990A2 (en) * | 2000-11-10 | 2002-05-16 | Vector Tobacco Ltd. | Method and product for removing carcinogens from tobacco smoke |
IL159213A0 (en) * | 2001-06-08 | 2004-06-01 | Vector Tobacco Ltd | Modifying nicotine and nitrosamine levels in tobacco |
US20060157072A1 (en) * | 2001-06-08 | 2006-07-20 | Anthony Albino | Method of reducing the harmful effects of orally or transdermally delivered nicotine |
EP1441603A2 (en) * | 2001-11-09 | 2004-08-04 | Vector Tobacco Inc. | Method and composition for mentholation of charcoal filtered cigarettes |
AP2004003146A0 (en) * | 2002-04-09 | 2004-09-30 | Vector Tobacco Ltd | Tobacco having reduced nicotine and nitrosamines |
US20050066986A1 (en) * | 2003-09-30 | 2005-03-31 | Nestor Timothy Brian | Smokable rod for a cigarette |
-
2004
- 2004-05-27 US US10/559,113 patent/US20060237025A1/en not_active Abandoned
- 2004-05-27 WO PCT/US2004/016958 patent/WO2005000352A1/en active Application Filing
- 2004-05-27 CA CA002527648A patent/CA2527648A1/en not_active Abandoned
- 2004-05-27 CN CNA2004800152795A patent/CN1812811A/en active Pending
- 2004-05-27 AU AU2004251635A patent/AU2004251635A1/en not_active Abandoned
- 2004-05-27 EP EP04776169A patent/EP1628681A4/en not_active Withdrawn
- 2004-05-27 KR KR1020057023265A patent/KR20060032141A/en not_active Application Discontinuation
- 2004-05-27 JP JP2006515013A patent/JP2007528204A/en active Pending
- 2004-06-03 AR ARP040101917A patent/AR044599A1/en not_active Application Discontinuation
-
2005
- 2005-12-14 ZA ZA200510170A patent/ZA200510170B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200510170B (en) | 2006-11-29 |
JP2007528204A (en) | 2007-10-11 |
KR20060032141A (en) | 2006-04-14 |
CN1812811A (en) | 2006-08-02 |
US20060237025A1 (en) | 2006-10-26 |
WO2005000352A1 (en) | 2005-01-06 |
AU2004251635A1 (en) | 2005-01-06 |
EP1628681A1 (en) | 2006-03-01 |
CA2527648A1 (en) | 2005-01-06 |
EP1628681A4 (en) | 2009-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR044599A1 (en) | METHOD FOR REDUCING THE HARMFUL EFFECTS OF NICOTINE ADMINISTERED BY ORAL OR TRANSDERMAL | |
Cogliano et al. | Smokeless tobacco and tobacco-related nitrosamines | |
Silva | Tobacco use and periodontal disease—the role of microvascular dysfunction | |
JP2017501714A (en) | Liquid composition for electronic cigarette | |
AR060931A1 (en) | PHARMACEUTICAL PRODUCT COVERED FOR INTRAORAL ADMINISTRATION OF NICOTINE AND ITS USE AND PREPARATION | |
DK1458252T3 (en) | Tobacco and / or tobacco in combination with tobacco substitute composition for use as snus in the oral cavity | |
HUP0400161A2 (en) | Modifying nicotine and nitrosamine levels in tobacco | |
RU2014134073A (en) | ORAL PRODUCT | |
BRPI0413733A (en) | low exposure tobacco products | |
EA200301202A1 (en) | HIDDEN TOBACCO PRODUCT | |
US9538782B2 (en) | Inhibition of sensory irritation during consumption of smokeless tobacco products using a combinatorial approach | |
NO20084992L (en) | Pharmaceutical product for intraoral delivery of nicotine including trometamol as a buffering agent | |
AR047141A1 (en) | SMOKING ITEM | |
AR044383A1 (en) | VARENICLINE PHARMACEUTICAL COMPOSITIONS | |
US20050034738A1 (en) | Chewing tobacco substitute containing nicotine | |
BR112022023812A2 (en) | TOBACCO-FREE ORAL NICOTINE POUCH COMPOSITION | |
KR102038342B1 (en) | Nicotine formulation | |
KR101257828B1 (en) | Composition of antismoking aid containing damascone | |
Sharma et al. | Novel pathways and mechanisms of Nicotine-Induced oral carcinogenesis | |
US20060112965A1 (en) | Chewing tobacco substitute containing cotinine | |
DE502004002023D1 (en) | TOBACCO MIXING, AND A CIGARETTE CONTAINING THEREOF | |
Sintija et al. | The oral microbiome of smokeless tobacco users in Latvia | |
FI127620B (en) | Snuff-type composition of nicotine and crushed linseed | |
Ramachandran et al. | Activation of platelets exposed to shear stress in the presence of smoke extracts of low-nicotine and zero-nicotine cigarettes: the protective effect of nicotine | |
Viegas | Noncigarette forms of tobacco use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |